| NCT05673057 | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | RECRUITING | PHASE1, PHASE2 | 2022-12-29 | 2029-12 | 2027-12 |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | TERMINATED | PHASE1 | 2021-10-11 | 2024-01-19 | 2024-01-19 |
| NCT04834856 | Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients | COMPLETED | PHASE2 | 2021-04-01 | 2021-08-20 | 2021-08-20 |
| NCT04870164 | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) | TERMINATED | PHASE1 | 2020-11-18 | 2022-01-06 | 2022-01-06 |
| NCT04049903 | Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2019-09-02 | 2022-12-21 | 2022-06-27 |
| NCT03418532 | MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | TERMINATED | PHASE1 | 2018-03-22 | 2020-04-24 | 2019-08-30 |
| NCT03084926 | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors | COMPLETED | PHASE1 | 2017-08-08 | 2021-12-13 | 2021-12-13 |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | COMPLETED | PHASE1, PHASE2 | 2017-05-23 | 2021-01-13 | 2020-10-12 |
| NCT02194426 | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients | COMPLETED | PHASE1, PHASE2 | 2014-07 | 2018-02-20 | 2018-02-20 |